SODIUM POLYSTYRENE SULFONATE powder, for suspension

SODIUM POLYSTYRENE SULFONATE by

Drug Labeling and Warnings

SODIUM POLYSTYRENE SULFONATE by is a Prescription medication manufactured, distributed, or labeled by SUNRISE PHARMACEUTICAL, INC., SUNRISE PHARMACEUTICAL INC.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    Sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia.

    Limitation of Use:

    Sodium polystyrene sulfonate for suspension should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2)]

  • 2 DOSAGE AND ADMINISTRATION

    2.1 General Information

    Administer sodium polystyrene sulfonate at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation [see Warnings and Precautions(5.5) and Drug Interaction(7)]

    2.2 Recommended Dosage

    The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia.

    Oral

    The average total daily adult dose of sodium polystyrene sulfonate is 15 g to 60 g, administered as a 15-g dose (four level teaspoons), one to four times daily.

    Rectal

    The average adult dose is 30 g to 50 g every six hours.

    2.3 Preparation and Administration

    Prepare suspension fresh and use within 24 hours.

    Do not heat sodium polystyrene sulfonate as it could alter the exchange properties of the resin.

    One level teaspoon contains approximately 3.5 g of sodium polystyrene sulfonate and 15 mEq of sodium.

    Oral Suspension

    Suspend each dose in a small quantity of water or syrup, approximately 3 to 4 mL of liquid per gram of resin. Administer with patient in an upright position [see Warnings and Precautions (5.4)].

    Enema

    After an initial cleansing enema, insert a soft, large size (French 28) rubber tube into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and tape in place.

    Administer as a warm (body temperature) emulsion in 100 mL of aqueous vehicle and flush with 50 to 100 ml of fluid. A somewhat thicker suspension may be used, but do not form a paste.

    Agitate the emulsion gently during administration. The resin should be retained for as long as possible and follow by a cleansing enema with a nonsodium containing solution. Ensure an adequate volume of cleansing solution (up to 2 liters) is utilized.

  • 3 DOSAGE FORMS AND STRENGTHS

    Sodium polystyrene sulfonate for suspension is a golden brown, finely ground powder and is available in 454 g jars and 15 g bottles.

  • 4 CONTRAINDICATIONS

    Sodium polystyrene sulfonate is contraindicated in patients with the following conditions:

    • Hypersensitivity to polystyrene sulfonate resins
    • Obstructive bowel disease
    • Neonates with reduced gut motility
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Intestinal Necrosis

    Cases of intestinal necrosis, some fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with sodium polystyrene sulfonate use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of sorbitol is not recommended.

    • Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery.
    • Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction). Discontinue use in patients who develop constipation.

    5.2 Electrolyte Disturbances

    Monitor serum potassium during therapy because severe hypokalemia may occur.

    Sodium polystyrene sulfonate is not totally selective for potassium, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Monitor calcium and magnesium in patients receiving sodium polystyrene sulfonate.

    5.3 Fluid Overload in Patients Sensitive to High Sodium Intake

    Each 15 g dose of sodium polystyrene sulfonate contains 1500 mg (60 mEq) of sodium. Monitor patients who are sensitive to sodium intake (heart failure, hypertension, edema) for signs of fluid overload. Adjustment of other sources of sodium may be required.

    5.4 Risk of Aspiration

    Cases of acute bronchitis or bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles have been reported. Patients with impaired gag reflex, altered level of consciousness, or patients prone to regurgitation may be at increased risk. Administer sodium polystyrene sulfonate with the patient in an upright position.

    5.5 Binding to Other Orally Administered Medications

    Sodium polystyrene sulfonate may bind orally administered medications, which could decrease their gastrointestinal absorption and lead to reduced efficacy. Administer other oral medications at least 3 hours before or 3 hours after sodium polystyrene sulfonate. Patients with gastroparesis may require a 6 hour separation. [see Dosage and Administration (2.1) and Drug Interactions (7)].

  • 6 ADVERSE REACTIONS

    The following adverse reactions are discussed elsewhere in the labeling:

    The following adverse reactions have been identified during post-approval use of sodium polystyrene sulfonate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.

    Gastrointestinal: anorexia, constipation, diarrhea, fecal impaction, gastrointestinal concretions (bezoars), ischemic colitis, nausea, ulcerations, vomiting, gastric irritation, intestinal obstruction (due to concentration of aluminium hydroxide)

    Metabolic: systemic alkalosis

  • 7 DRUG INTERACTIONS

    7.1 General Interactions

    No formal drug interaction studies have been conducted in humans.

    Sodium polystyrene sulfonate has the potential to bind other drugs. In in vitro binding studies, sodium polystyrene sulfonate was shown to significantly bind the oral medications (n=6) that were tested. Decreased absorption of lithium and thyroxine have also been reported with co-administration of sodium polystyrene sulfonate. Binding of sodium polystyrene sulfonate to other oral medications could cause decreased gastrointestinal absorption and loss of efficacy when taken close to the time sodium polystyrene sulfonate is administered. Administer sodium polystyrene sulfonate at least 3 hours before or 3 hours after other oral medications. Patients with gastroparesis may require a 6 hour separation. Monitor for clinical response and/or blood levels where possible.

    7.2 Cation-Donating Antacids

    The simultaneous oral administration of sodium polystyrene sulfonate with nonabsorbable cation-donating antacids and laxatives may reduce the resin's potassium exchange capability and increase the risk of systemic alkalosis.

    7.3 Sorbitol

    Sorbitol may contribute to the risk of intestinal necrosis [see Warnings and Precautions (5.1)] and concomitant use is not recommended.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration and maternal use is not expected to result in fetal risk.

    8.2 Lactation

    Risk Summary

    Sodium polystyrene sulfonate is not absorbed systemically by the mother, so breastfeeding is not expected to result in risk to the infant.

    8.4 Pediatric Use

    Studies of safety and efficacy have not been conducted in pediatric patients.

    In pediatric patients, as in adults, sodium polystyrene sulfonate is expected to bind potassium at the practical exchange ratio of 1mEq potassium per 1 gram of resin.

    In neonates, sodium polystyrene sulfonate should not be given by the oral route. In both children and neonates, excessive dosage or inadequate dilution could result in impaction of the resin. Premature infants or low birth weight infants may have an increased risk for gastrointestinal adverse effects with sodium polystyrene sulfonate use [see Warnings and Precautions (5.4)].

  • 10 OVERDOSAGE

    Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas.

  • 11 DESCRIPTION

    Sodium polystyrene sulfonate is a benzene, diethenyl- polymer, with ethenylbenzene,
    sulfonated, sodium salt and has the following structural formula:

    image descriptionn

    The drug is a golden brown finely ground, powdered form of sodium polystyrene sulfonate, a cation-exchange resin prepared in the sodium phase with an in vitro exchange capacity of approximately 3.1 mEq (in vivo approximately 1 mEq) of potassium per gram. The sodium content is approximately 100 mg (4.1 mEq) per gram of the drug. It can be administered orally or in an enema.

    One gram of sodium polystyrene sulfonate contains 4.1 mEq of sodium.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Sodium polystyrene sulfonate is a non-absorbed, cation exchange polymer that contains a sodium counterion.

    Sodium polystyrene sulfonate increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels. The practical exchange ratio is 1 mEq K per 1 gram of resin.

    As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. This action occurs primarily in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable.

    12.2 Pharmacodynamics

    The effective lowering of serum potassium with sodium polystyrene sulfonate may take hours to days.

    12.3 Pharmacokinetics

    The in vivo efficiency of sodium-potassium exchange resins is approximately 33 percent; hence, about one third of the resin's actual sodium content is delivered to the body.

    Sodium polystyrene sulfonate is not absorbed systemically.

    Drug Interactions

    In vitro binding studies showed that sodium polystyrene sulfonate bound significantly to the following tested drugs – warfarin, metoprolol, phenytoin, furosemide, amlodipine and amoxicillin.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Studies have not been performed.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Sodium polystyrene sulfonate for suspension is available as a golden brown, finely ground powder in jars of 1 pound (454 g), NDC: 11534-166-44, in bottles of 15 g, NDC: 11534-166-16 and 10 in 1 carton pack of 15 g per bottle, NDC: 11534-166-15

    Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]

  • 17 PATIENT COUNSELING INFORMATION

    Drug Interactions

    Advise patients who are taking other oral medication to separate the dosing of sodium polystyrene sulfonate by at least 3 hours (before or after) [see Dosage and Administration (2.1), Warnings and Precautions (5.5), and Drug Interactions (7.1)]

    Rx Only

    Manufactured & Distributed by:
    Sunrise Pharmaceutical, Inc.
    Rahway, NJ 07065

    Revised March 2020
    5082/06

  • PRINCIPAL DISPLAY PANEL - 15 g Bottle (10 in 1 Carton)

    NDC 11534- 166 -15

    Sodium Polystyrene

    Sulfonate for

    Suspension

    15 g

    Read package outsert.

    Rx only

    SUNRISE PHARMA

    image description

  • PRINCIPAL DISPLAY PANEL - 15 g Bottle

    NDC 11534- 166 -16

    Sodium Polystyrene

    Sulfonate for

    Suspension

    15 g

    Read package outsert.

    Rx only

    SUNRISE PHARMA

    image description

  • PRINCIPAL DISPLAY PANEL - 454 g Bottle

    NDC 11534- 166 -44

    Sodium Polystyrene

    Sulfonate for

    Suspension

    454 g (1 lb)

    Read package outsert.

    Rx only

    SUNRISE PHARMA

    image description

  • INGREDIENTS AND APPEARANCE
    SODIUM POLYSTYRENE SULFONATE 
    sodium polystyrene sulfonate powder, for suspension
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 11534-166
    Route of AdministrationORAL, RECTAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    SODIUM POLYSTYRENE SULFONATE (UNII: 1699G8679Z) (POLYSTYRENE SULFONIC ACID - UNII:70KO0R01RY) SODIUM CATION4.1 meq  in 1 g
    Product Characteristics
    ColorBROWN (GOLDEN) Score    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 11534-166-44454 g in 1 JAR; Type 0: Not a Combination Product01/24/2017
    2NDC: 11534-166-1515 g in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    3NDC: 11534-166-1615 g in 1 BOTTLE; Type 0: Not a Combination Product01/24/2017
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20407101/24/2017
    Labeler - SUNRISE PHARMACEUTICAL, INC. (168522378)
    Registrant - SUNRISE PHARMACEUTICAL, INC. (168522378)
    Establishment
    NameAddressID/FEIBusiness Operations
    SUNRISE PHARMACEUTICAL INC.168522378ANALYSIS(11534-166) , LABEL(11534-166) , PACK(11534-166)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.